1,2-dibromobenzene | CAS:583-53-9

We serve 1,2-dibromobenzene CAS:583-53-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,2-dibromobenzene

Chemical Name:1,2-dibromobenzene
CAS.NO:583-53-9
Synonyms:1,2-Dibrombenzol
Molecular Formula:C6H4Br2
Molecular Weight:235.90400
 
Physical and Chemical Properties:
Density:1.956;
Melting point:4-6oC;
Boiling point:224oC;
Flash point:91oC;
Index of Refraction:1.611;
 
Specification:
Appearance:Colorless or orange liquid
Purity(GC):≥99.0%
Moisture:≤0.1%
 
Packing:250 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As an intermediate in organic synthesis
 



Contact us for information like 1,2-dibromobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2-Dibrombenzol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2-dibromobenzene Use and application,1,2-Dibrombenzol technical grade,usp/ep/jp grade.


Related News: The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island.1-(2-Methoxyphenyl)piperazine hydrochloride manufacturer Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.Methyl N-cyanoethanimideate supplier Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.1-(3-chloropropyl)-4-methylpiperazine,dihydrochloride vendor The KCDC said a 28-year-old man had tested positive. He was among the 368 repatriated South Koreans who arrived from Wuhan on a charter flight on January 31. The rest of the evacuees have tested negative for the coronavirus.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.